Società Eli Lilly and Company Deutsche Boerse AG

LLY

US5324571083

Prodotti farmaceutici

Consensus Analisti

Attività

Vendite per attività

Vendite per regione

Dirigenti

Amministratori

Classe di azioni

Azionisti

Partecipazioni

Coordinate società

Società del gruppo

Settore

Vendite per regione

Rating per Eli Lilly and Company

Revisioni EPS

Utili trimestrali - Indice di sorpresa

Settore Prodotti farmaceutici - Altri

Mercato chiuso - Deutsche Boerse AG Altri mercati azionari 17:18:49 17/05/2024			Variaz. 5gg	Var. 1 gen.
709,2 ^EUR	-0,70%		-0,44%	+34,70%

16/05	Totus Medicines Inc. annuncia una collaborazione strategica di ricerca multi-target con Eli Lilly and Company	CI
16/05	L'insulina una volta alla settimana Efsitora Alfa di Eli Lilly ha raggiunto l'endpoint primario in studi di fase avanzata	MT

Eli Lilly and Company è uno dei gruppi farmaceutici leader a livello mondiale. Le vendite nette sono così suddivise per settore terapeutico:
- endocrinologia (57,7%): prodotti per il trattamento dell'osteoporosi, del diabete e dei problemi di crescita;
- oncologia (19,5%);
- malattie immunologiche (11,1%);
- neurologia (8,4%): principalmente farmaci utilizzati nel trattamento della depressione e della schizofrenia;
- altro (3,3%).
Le vendite nette sono distribuite geograficamente come segue: Stati Uniti (63,9%), Europa (18,1%), Giappone (4,9%), Cina (4,5%) e altro (8,6%).

Numero di dipendenti: 43 000

USD in Milioni	2022	Peso	2023	Peso	Delta
Human Pharmaceutical Products 100,0 %	28 541	100,0 %	34 124	100,0 %	+19,56%

USD in Milioni	2022	Peso	2023	Peso	Delta
United States 63,9 %	18 190	63,7 %	21 791	63,9 %	+19,80%
Europe 18,1 %	4 299	15,1 %	6 175	18,1 %	+43,62%
Other Foreign Countries 8,6 %	2 852	10,0 %	2 946	8,6 %	+3,30%
Japan 4,9 %	1 747	6,1 %	1 673	4,9 %	-4,28%
China 4,5 %	1 453	5,1 %	1 540	4,5 %	+5,98%

Dirigenti	Titolo	Età	Da
David Ricks CEO	Chief Executive Officer	56	01/01/96
Anat Ashkenazi DFI	Director of Finance/CFO	51	01/01/01
Ruth Gimeno PSD	President	-	-
Diogo Rau CTO	Chief Tech/Sci/R&D Officer	-	17/05/21
David Hyman CTO	Chief Tech/Sci/R&D Officer	-	16/10/23
Alonzo Weems CMP	Compliance Officer	-	01/01/97
Daniel Skovronsky CTO	Chief Tech/Sci/R&D Officer	50	01/01/18
Edgardo Hernandez PRN	Corporate Officer/Principal	-	01/01/05
Ilya Yuffa PRN	Corporate Officer/Principal	49	-
Ronald DeMattos PRN	Corporate Officer/Principal	-	-

Amministratori	Titolo	Età	Da
Gabrielle Greene-Sulzberger BRD	Director/Board Member	63	25/01/21
Ralph Alvarez BRD	Director/Board Member	68	01/04/09
Jon Fyrwald BRD	Director/Board Member	63	01/01/05
Juan Luciano BRD	Director/Board Member	62	01/02/16
William Kaelin BRD	Director/Board Member	66	04/06/12
David Ricks CEO	Chief Executive Officer	56	01/01/96
Jamere Jackson BRD	Director/Board Member	54	01/10/16
Katherine Baicker BRD	Director/Board Member	52	12/12/11
Marschall Runge BRD	Director/Board Member	69	01/09/13
Karen Walker BRD	Director/Board Member	62	01/12/18

	Voto	Quantità	Flottante	Autocontrollo	Flottante totale
Azione A	1	950 770 386	948 828 863 ( 99,80 %)	365 000 ( 0,0384 %)	99,80 %

Nome	Azioni	%	Valorizzazione
Lilly Endowment, Inc. 10,40 %	98 898 810	10,40 %	77 250 M €
Vanguard Fiduciary Trust Co. 7,651 %	72 745 011	7,651 %	56 821 M €
The Vanguard Group, Inc. 7,531 %	71 604 696	7,531 %	55 930 M €
PNC Investments LLC 5,410 %	51 438 196	5,410 %	40 178 M €
BlackRock Advisors LLC 5,286 %	50 259 761	5,286 %	39 258 M €
STATE STREET CORPORATION 3,603 %	34 258 566	3,603 %	26 759 M €
Fidelity Management & Research Co. LLC 3,583 %	34 063 734	3,583 %	26 607 M €
Capital Research & Management Co. (World Investors) 2,581 %	24 536 055	2,581 %	19 165 M €
PRIMECAP Management Co. 2,235 %	21 254 190	2,235 %	16 602 M €
T. Rowe Price International Ltd. 2,168 %	20 613 061	2,168 %	16 101 M €

Nome	Azioni	%	Valorizzazione
Caixa DTVM SA 0,001476 %	421 310	0,001476 %	11 M €
Western Asset Management Company DTVM Ltda. 0,000707 %	201 841	0,000707 %	5 M €
Bram Bradesco Asset Management S/A DTVM 0,000172 %	49 010	0,000172 %	1 M €
Safra Asset Management Ltda. 0,000157 %	44 900	0,000157 %	1 M €
Warren Brasil Gestão e Administração e Recursos Ltda. 0,000041 %	11 739	0,000041 %	306 866 €
XP Allocation Asset Management Ltda. 0,000014 %	3 883	0,000014 %	101 504 €
BTG Pactual WM Gestão de Recursos Ltda. 0,000009 %	2 450	0,000009 %	64 045 €

Nome	Azioni	%	Valorizzazione
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. 6.83%	8 084 411	6.83%	50 293 848 $
PROQR THERAPEUTICS N.V. 16.55%	13 371 562	16.55%	26 208 262 $
FOGHORN THERAPEUTICS INC. 9.40%	4 000 000	9.40%	20 920 000 $
MICROTECH MEDICAL (HANGZHOU) CO., LTD. 7.60%	21 776 804	7.60%	11 332 213 $
AC IMMUNE SA 3.64%	3 615 328	3.64%	8 279 101 $
PRECISION BIOSCIENCES, INC. 1.81%	125 405	1.81%	1 218 937 $

Eli Lilly & Co.

Lilly Corporate Center

46285, Indianapolis

+317 276 2000

http://www.lilly.com

Nome	Categoria e settore
ELI Lilly & Company (India) Pvt Ltd. ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India.	Pharmaceuticals: Major
Eli Lilly Services India Pvt Ltd. Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015.	Pharmaceuticals: Major
Eli Lilly Export SA (Switzerland) Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide.	Medical Distributors
Kinsale Financial Services
Lilly Nederland Finance BV Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The company is based in Utrecht, Netherlands.	Miscellaneous Commercial Services
Eli Lilly SA Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland.	Pharmaceuticals: Major
Eli Lilly (Suisse) SA
Lilly Global Nederland Holdings BV Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The company is based in Utrecht, Netherlands.	Financial Conglomerates
Eli Lilly Vostok SA
Lilly Ventures Fund I LLC Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements.	Investment Managers
Eli Lilly Kinsale Ltd. Eli Lilly Kinsale Ltd. Pharmaceuticals: OtherHealth Technology Eli Lilly Kinsale Ltd., part of Eli Lilly & Co., is a company headquartered in Kinsale, Ireland, that manufactures medicines.	Pharmaceuticals: Other
Eli Lilly Group Pension Trustees Ltd. Eli Lilly Group Pension Trustees Ltd. Financial ConglomeratesFinance Part of Eli Lilly & Co., Eli Lilly Group Pension Trustees Ltd. operates as a British dormant company. The company is based in Basingstroke, UK.	Financial Conglomerates

Rating Trading

Rating Investimento

ESG Refinitiv

Altri rating

Vendita

Buy

Raccomandazione media

Buy

Numero di analisti

Ultimo prezzo di chiusura

770 USD

Prezzo obiettivo medio

850,4 USD

Differenza / Target Medio

+10,44%

Consenso

Revisioni delle Stime

Calendario della società

Biotecnologia/Farmaceutici

Biotecnologia/Farmaceutici

Prodotti farmaceutici

Prodotti farmaceutici - Altri

	Variaz. 1 gen.	Capi.
NOVO NORDISK A/S	+29,39%	584 Mrd
JOHNSON & JOHNSON	-1,34%	372 Mrd
MERCK & CO., INC.	+20,34%	332 Mrd
ABBVIE INC.	+7,39%	294 Mrd
ASTRAZENECA PLC	+14,25%	239 Mrd
ROCHE HOLDING AG	-3,03%	211 Mrd
NOVARTIS AG	+10,02%	210 Mrd
AMGEN INC.	+8,49%	168 Mrd
PFIZER, INC.	-0,52%	162 Mrd

Prodotti farmaceutici - Altri